ANI exec reports tax-withheld 3,011 ANIP shares

ANI Pharmaceuticals executive Meredith Cook reported a tax-related share disposition.

Accepted by SEC EDGAR 02/13/2026 - 04:13 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

ANI Pharmaceuticals executive Meredith Cook reported a tax-related share disposition. On February 11, 2026, 3,011 shares of ANI Pharmaceuticals common stock were disposed of at $76.25 per share to cover tax obligations tied to equity compensation.

The filing explains that these shares were withheld for tax purposes in connection with the vesting of 8,104 performance stock units, previously granted on April 6, 2023. After this tax-withholding transaction, Cook directly beneficially owned 71,363 shares of ANI Pharmaceuticals common stock.

Insider Trade Summary

Exercise Price or Tax Liability: 3,011 shares

Exercise Price or Tax Liability 1 txn

Insider Cook Meredith

Role SR. VP, GENERAL COUNSEL & SEC.

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	3,011	$76.25	$230K

Holdings After Transaction: Common Stock — 71,363 shares (Direct)

Holdings Before and After: Common Stock, 74,374 to 71,363 shares (Direct)

Footnotes (1)

1. F1. Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 8,104 performance stock units, the grant of which was previously reported on April 6, 2023.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ANI Pharmaceuticals (ANIP) report for Meredith Cook?

ANI Pharmaceuticals reported that executive Meredith Cook had 3,011 common shares disposed of to cover tax obligations. The transaction was linked to the vesting of performance stock units and was not an open-market buy or sell.

Was the ANI Pharmaceuticals (ANIP) Form 4 transaction a sale on the open market?

No, the Form 4 shows a tax-withholding disposition coded as “F,” meaning shares were withheld to pay taxes. It was connected to vesting equity awards rather than a discretionary open-market sale by the executive.

How many ANI Pharmaceuticals (ANIP) shares does Meredith Cook own after the transaction?

After the reported tax-withholding transaction, Meredith Cook directly beneficially owned 71,363 shares of ANI Pharmaceuticals common stock. This figure reflects her holdings following the 3,011 shares withheld for tax purposes on February 11, 2026.

What equity award triggered the tax withholding for ANI Pharmaceuticals (ANIP) executive Meredith Cook?

The tax withholding was triggered by the vesting of 8,104 performance stock units granted to Meredith Cook. The grant had been previously reported on April 6, 2023, and the vesting required shares to be withheld to satisfy tax liabilities.

What does transaction code “F” mean on the ANI Pharmaceuticals (ANIP) Form 4?

Transaction code “F” denotes payment of an exercise price or tax liability by delivering or withholding securities. In this case, 3,011 shares were withheld from Meredith Cook’s equity vesting to cover tax obligations instead of being sold on the market.

What role does Meredith Cook hold at ANI Pharmaceuticals (ANIP) in this Form 4 filing?

In the Form 4, Meredith Cook is identified as an officer of ANI Pharmaceuticals with the title “SR. VP, GENERAL COUNSEL & SEC.” This reflects her senior legal and corporate secretary responsibilities at the company when the transaction was reported.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cook Meredith

(Last) (First) (Middle)

C/O ANI PHARMACEUTICALS, INC.

210 MAIN STREET WEST

(Street)

BAUDETTE MN 56623

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ANI PHARMACEUTICALS INC [ ANIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SR. VP, GENERAL COUNSEL & SEC.

3. Date of Earliest Transaction (Month/Day/Year)
02/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/11/2026		F(1)		3,011	D	$76.25	71,363	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 8,104 performance stock units, the grant of which was previously reported on April 6, 2023.

Remarks:

	/s/ Meredith W. Cook	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.